How a biomaterials pilot study works

A biomaterials pilot study is a small, scoped study that tests whether a method can answer one question about your material, at your conditions, before you commit to a larger program. It should end in a decision: continue, change the method or stop. It won’t give you a reliable effect size or a safety finding, so a pilot’s value depends on asking it the right question.

What is a biomaterials pilot study?

A pilot study tests whether an approach works before a team spends on the larger study behind it. The sources checked here give no formal definition for biomaterials, so the closest one comes from clinical research, where Leon and colleagues describe the purpose as examining “the feasibility of an approach that is intended to be used in a larger scale study.”

Carried over to the bench, that’s three practical questions (the translation is ours):

• Handling: does the material survive the method? A gel can tear, float or clog a filter long before it gives you a number.
• Signal: does the readout move? If two candidates you expect to differ produce the same curve, the method can’t choose between them.
• Fit: do the conditions, duration and timepoints show the behavior you care about? A run that stops before mass starts to fall has nothing to say about degradation.

Which decision should a pilot settle?

A pilot should settle one decision that someone can name before the first sample is loaded. ICH’s development guideline Q8(R2) says the quality target product profile “forms the basis of design for the development of the product.” A pilot sits further upstream than that document, and the habit carries: start from what the product has to do, then choose what to measure.

Decision	What the pilot has to show	Typical readouts
Which formulation goes forward?	Candidates separate at the same conditions	Mass over time, drug in the medium
Can this method read this material?	Samples survive handling and readings agree across samples	Mass over time, images
Does a new lot behave like the old one?	Two lots run side by side by one method	Mass over time, rheology
Can a shorter run stand in for a long one?	Formulations keep their order at both conditions	Release at real-time and accelerated conditions

Accelerated runs carry a real risk. A 2026 review of PLGA release methods warns that burst, lag or secondary release phases may be diminished or lost under accelerated conditions. It also says a changed release mechanism may be acceptable if the accelerated method still discriminates and preserves rank order against real time. That makes the real-time arm the cost of the shortcut: you can’t validate a faster run without also running the slower one.

The readouts themselves belong to their own pages. For drug leaving a depot, see in vitro release testing for long-acting injectables. For the carrier changing, see polymer degradation testing.

What should the R&D leader and the bench scientist each bring?

The R&D leader brings the decision and the bench scientist brings what the material does in their hands. The study brief and scoping checklist puts both on one page.

• R&D leader: the decision, the date it has to be made, the scope you can approve, and who else signs off.
• Bench scientist: the sample format, how the material behaves when handled, the medium you’d use, and what your current method misses.
• Quality, when the buyer is regulated: what the data has to be good for, raised before the study rather than after it.

Agree on what the pilot can’t do while you’re at it. Leon and colleagues tell investigators to be forthright about a pilot’s objectives, and they write that grant reviewers and other stakeholders “should expect no more.” Your budget holder is that stakeholder.

How does a pilot study run, step by step?

A GelTech pilot runs from a first message through a scoping call and a formal quote to a run in GelTech’s lab, and it ends with a dataset and report.

1. First message: tell GelTech the material and what the data needs to show. The first consultation is on GelTech. Leave out confidential formulation details at this stage.
2. Scoping call: a call scopes the study to your material and to what the data needs to show.
3. Confidentiality: when a project needs an agreement, GelTech puts it in place first, before confidential detail changes hands.
4. Formal quote: GelTech sends a formal quote once the call has scoped the study. The quote lists the conditions, timepoints, replicates and report.
5. Samples or a brief: you ship samples, or you send a brief and GelTech formulates. Most samples ship at room temperature, and cold shipments are less common. Leftover sample is disposed of or sent back to you.
6. The run: GelTech runs the study in its lab.
7. Dataset and report: each study returns a dataset and a report. Carousel’s raw output is .csv data files and .jpg images of each sample.
8. Next step: you take the decision from there, whether that’s a larger study, another pilot or no further work.

How big should a pilot be?

A pilot should be as small as the decision allows, and no study this small can size the next one. Leon and colleagues write that a pilot “does not provide a meaningful effect size estimate for planning subsequent studies due to the imprecision inherent in data from small samples.” They’re writing about clinical trials. The arithmetic of small samples doesn’t change at the bench, but your own variance data may be better evidence for planning than the pilot’s mean difference.

Three choices set the size, and each has a cost:

• Formulations against replicates: Carousel runs six samples at once per unit, so a single unit could carry three formulations in duplicate or two in triplicate (this page’s arithmetic). More candidates means less confidence in each.
• Lots: one lot can’t tell you about a material. Fu and colleagues tested ten batches of one pharmaceutical grade of sodium alginate, and the batches differed in rheological properties, especially at higher concentrations. Adding a lot takes chambers away from something else.
• Duration: long-acting products deliver over weeks or months, and the same review notes that real-time testing takes that long too. Stopping early saves time and leaves the late behavior unmeasured.

Which claims can’t pilot data support?

A pilot can’t establish safety, efficacy or a difference you can defend statistically. Leon and colleagues are direct on this: a pilot “is not a hypothesis testing study”, safety and efficacy aren’t evaluated in one, and its results don’t necessarily generalize beyond its own design.

FDA’s Good Laboratory Practice rule defines a nonclinical laboratory study as one that determines safety, and 21 CFR 58.3 says the term doesn’t include “basic exploratory studies” carried out to determine a test article’s potential utility or its physical or chemical characteristics. A pilot that measures swelling and release reads as the second kind. Ask your regulatory lead how that applies to your program before you plan on reusing the data.

A material made in a small batch and tested once says little about what it does after scale-up, sterilization and storage, which is the gap Sinan’s newsletter on commercialization walks through.

GelTech’s own scope ends earlier than a full development program. GelTech doesn’t run animal or clinical studies, and it doesn’t offer accredited biocompatibility or sterility testing.

What happens after a pilot?

A pilot should leave you able to continue, change the method or stop, and each of those is a useful result. Leon and colleagues say pilot results can “identify modifications needed in the design of a larger” study, which is often the most valuable output: a medium that needs changing, a timepoint schedule that missed the peak, a sample format that clogged the filter.

If you continue, the next question is where the work runs. Outsource a study or buy an instrument covers that decision, and choosing a biomaterials testing partner covers what to check in a lab before you commit further.

What does a GelTech pilot study measure?

A GelTech pilot measures how your material behaves over time in fluid, and it reads the rest on integrated instruments. Carousel weighs each sample to 1 mg at every timepoint, six samples at once, for minutes to months, at temperatures from ambient to 60 °C and in media from pH 1.5 to 12. GelTech puts its mass data at roughly 3x less data variability than manual work. Integrated instruments such as UV-Vis, HPLC, LC-MS, FTIR and rheometry read the drug, the mechanics and the chemistry.

Samples can be powders, films and sheets, tablets, injectables, microparticles, amorphous gels, foams or implants. Carousel’s spec sheet lists a 25 mg minimum dry sample mass and a 24 mL chamber, so a smaller sample or a study that needs more medium gets sorted out on the scoping call.

GelTech’s aim is for better candidates to reach animal and clinical studies sooner, starting from a pilot on your material. See GelTech’s R&D services for the full menu.

Sources

• Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45(5):626-629
• US Code of Federal Regulations, 21 CFR 58.3, Definitions (Good Laboratory Practice for Nonclinical Laboratory Studies)
• FDA and ICH. Q8(R2) Pharmaceutical Development, guidance for industry, November 2009
• Lusina Kregar M, Krtalić I, Šagud I. An overview of in vitro release methods for long-acting injectable products based on PLGA. Methods Protoc. 2026;9(3):87
• Fu S, Thacker A, Sperger DM, et al. Rheological evaluation of inter-grade and inter-batch variability of sodium alginate. AAPS PharmSciTech. 2010;11(4):1662-1674
• GelTech Labs, R&D services page
• GelTech Labs, Carousel page and spec sheet
• GelTech Labs, terms of use, confidential information and ideas

Related reading

• Study brief and scoping checklist for biomaterials testing
• In vitro release testing for long-acting injectable depots
• Polymer degradation testing in drug delivery depots